What it is
DSIP (Delta Sleep-Inducing Peptide) is a naturally occurring nonapeptide first isolated from rabbit cerebral venous blood during EEG delta-sleep states. It is investigated for support of healthy sleep patterns, calming of the nervous system, deeper rest, and stress-response and recovery during physical and mental strain.
Mechanism of action
Modulates GABAergic and opioidergic systems, influences hypothalamic-pituitary-adrenal axis output, and may shift EEG architecture toward slow-wave (delta) sleep. Exact receptor targets remain incompletely characterised.
Half-life: Short — minutes to ~30 minutes in plasma.
Evidence summary
Original 1981 clinical work showed improvements in disturbed sleep. Modern reviews summarise its broader stress-modulation profile. Robust large-scale RCTs are limited.
Typical dosing protocols
- 100–500 mcg subcutaneous, ~30–60 minutes pre-bed
- 4-week cycles common
- Often combined with magnesium / sleep-hygiene routine
Side effects & safety
- Generally well-tolerated; mild dizziness or headache possible
- Vivid dreams reported anecdotally
- Long-term human safety data is limited
Cited studies
- (1981). The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep. Experientia (NLM).Read source ↗
- (2019). Delta sleep-inducing peptide. Reference Module in Biomedical Sciences (ScienceDirect).Read source ↗
- (2025). DSIP Peptide: Benefits, Dosage, Side Effects & Clinical Data. Exploring Peptides (clinical review).Read source ↗
All content is for research and educational purposes. Peptides described are sold for laboratory research use only and are not intended to diagnose, treat, cure, or prevent any disease. Always consult a qualified healthcare professional before beginning any protocol.
